The Cogstate Blog

Expert perspectives on improving cognitive measures from clinical trials to clinical practice.

Cogstate Participation at CTAD 2017

November 20, 2017

In this video Cogstate CSO, Prof Paul Maruff, discusses the recent Clinical Trials in Alzheimer’s Disease (CTAD) conference and the exciting scientific contributions from Cogstate, as featured in the following presentations:

  • Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai elenbecestat MissionAD phase 3 clinical trials
  • Utility of the International Shopping List Test for detection of memory impairment associated with prodromal and early Alzheimer’s disease in clinical trials
  • Phase IIa study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer’s Disease
  • Online study partner-reported subjective cognitive decline can help identify potential Alzheimer’s clinical trial participants
  • UB-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease
  • Rapid, Remote, and Repeatable: Smartphone-Based “Burst” Cognitive Assessments for Global AD Prevention Trials